📊 DXCM Key Takeaways
Is DXCM a Good Investment? Thesis Analysis
Dexcom demonstrates exceptional financial health with robust profitability growth (Net Income +45.1% YoY), strong margins across all levels (60.1% gross, 19.6% operating, 17.9% net), and impressive cash generation (1.4B operating cash flow, 23.1% FCF margin). The company maintains fortress-like balance sheet strength with minimal debt (0.00x debt/equity), strong liquidity (1.88x current ratio), and generates substantial free cash flow relative to revenue, positioning it well for sustained growth and shareholder returns.
Why Buy DXCM? Key Strengths
- Exceptional profitability growth with Net Income +45.1% YoY and EPS +47.2% YoY indicating strong operational leverage
- Premium gross margins at 60.1% demonstrating pricing power and efficient cost of goods sold management
- Best-in-class capital efficiency with ROE of 30.5% and ROA of 13.2% showing excellent asset utilization
- Outstanding cash generation with 1.4B operating cash flow and 23.1% FCF margin providing strategic flexibility
- Pristine balance sheet with negligible debt (2.9M long-term debt), strong cash position (917.7M), and fortress-like financial stability
- Reliable revenue growth of 15.6% YoY demonstrates sustained market demand and recurring revenue model characteristics
DXCM Investment Risks to Consider
- High insider trading activity (14 Form 4 filings in 90 days) warrants monitoring for potential signaling concerns
- Medical device sector faces regulatory pressures, reimbursement rate changes, and competitive dynamics from larger incumbents
- Margin sustainability dependent on maintaining pricing power and controlling manufacturing costs in competitive market
Key Metrics to Watch
- Operating margin trend - critical to confirm operational leverage sustainability
- Free cash flow generation and conversion ratio - essential metric for long-term value creation
- Revenue growth rate - monitor for deceleration signaling market saturation or competitive loss
- Return on equity trajectory - track to ensure capital efficiency remains above 25%
- Gross margin stability - watch for compression from pricing pressure or manufacturing cost inflation
DXCM Financial Metrics
💡 AI Analyst Insight
The 23.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
DXCM Profitability Ratios
DXCM vs Healthcare Sector
How DEXCOM INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DXCM Overvalued or Undervalued?
Based on fundamental analysis, DEXCOM INC appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DXCM Balance Sheet & Liquidity
DXCM 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: DEXCOM INC's revenue has grown significantly by 90% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.30 reflects profitable operations.
DXCM Growth Metrics (YoY)
DXCM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $994.2M | $134.6M | $0.34 |
| Q2 2025 | $1.0B | $143.5M | $0.35 |
| Q1 2025 | $921.0M | $105.4M | $0.27 |
| Q3 2024 | $975.0M | $120.7M | $0.29 |
| Q2 2024 | $871.3M | $115.9M | $0.28 |
| Q1 2024 | $741.5M | $48.6M | $0.12 |
| Q3 2023 | $769.6M | $101.2M | $0.24 |
| Q2 2023 | $696.2M | $50.9M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DXCM Capital Allocation
DXCM SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for DEXCOM INC (CIK: 0001093557)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773864421.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773172919.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773172914.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773172906.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773172900.xml | View → |
❓ Frequently Asked Questions about DXCM
What is the AI rating for DXCM?
DEXCOM INC (DXCM) has an AI rating of STRONG BUY with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DXCM's key strengths?
Claude: Exceptional profitability growth with Net Income +45.1% YoY and EPS +47.2% YoY indicating strong operational leverage. Premium gross margins at 60.1% demonstrating pricing power and efficient cost of goods sold management.
What are the risks of investing in DXCM?
Claude: High insider trading activity (14 Form 4 filings in 90 days) warrants monitoring for potential signaling concerns. Medical device sector faces regulatory pressures, reimbursement rate changes, and competitive dynamics from larger incumbents.
What is DXCM's revenue and growth?
DEXCOM INC reported revenue of $4.7B.
Does DXCM pay dividends?
DEXCOM INC does not currently pay dividends.
Where can I find DXCM SEC filings?
Official SEC filings for DEXCOM INC (CIK: 0001093557) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DXCM's EPS?
DEXCOM INC has a diluted EPS of $2.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DXCM a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, DEXCOM INC has a STRONG BUY rating with 92% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is DXCM stock overvalued or undervalued?
Valuation metrics for DXCM: ROE of 30.5% (sector avg: 15%), net margin of 17.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy DXCM stock in 2026?
Our dual AI analysis gives DEXCOM INC a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is DXCM's free cash flow?
DEXCOM INC's operating cash flow is $1.4B, with capital expenditures of $363.5M. FCF margin is 23.1%.
How does DXCM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.9% (avg: 12%), ROE 30.5% (avg: 15%), current ratio 1.88 (avg: 2).